Live Breaking News & Updates on University Of Houston College Pharmacy

Stay updated with breaking news from University of houston college pharmacy. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

A new weapon against the super tough C diff bacteria

A new weapon against the super tough C diff bacteria
sciencedaily.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from sciencedaily.com Daily Mail and Mail on Sunday newspapers.

Texas , United-states , University-of-houston , Blakem-hanson , Hossaena-ayele , Robertl-boblitt , Jinhee-jo , Kevin-garey , University-of-houston-college-pharmacy , Uh-college-of-pharmacy , Endowed-professor , Drug-discovery

A New Weapon Against the Super Tough C Diff Bacteria - University of Houston

Phase 1 Trial Shows New RX Fights C Diff and Spares Healthy Microbiota ....

Texas , United-states , University-of-houston , Blakem-hanson , Jinhee-jo , Robertl-boblitt , Hossaena-ayele , Kevin-garey , University-of-houston-college-pharmacy , Uh-college-of-pharmacy , Endowed-professor , Drug-discovery

Acurx Announces Positive Phase 2b Results Showing 100% of Patients Who Had Clinical Cure with Ibezapolstat Also Had Sustained Clinical Cure

All 15 ibezapolstat-treated patients in Phase 2b who achieved Clinical Cure at end of treatment remained free of C. difficile Infection recurrence through one month after EOT, for a Sustained. ....

United-states , America , Kevin-garey , Stuart-johnson , Robertj-deluccia , Davidp-luci , Acurx-pharmaceuticals-inc , Infectious-diseases-society-of-america , University-of-houston-college-pharmacy , Data-monitoring-committee , Exchange-commission-on-form , Drug-administration

Phase 2 Trial Data Show That Novel Antibiotic Led to 96% Cure Rate for C diff Infection

Iberzaplstat was non-inferior to standard of care vancomycin, was safe and tolerable, and will advance into a phase 3 trial.
....

United-states , Jo-panuwat , Stuart-johnson , Robertj-deluccia , Kevin-garey , Acrux-pharmaceuticals , University-of-houston-college-pharmacy , Us-centers-for-disease , Loyola-university , Pfizer , Acurx-scientific-advisory-board , Houston-college

Acurx Pharmaceuticals, Inc. (NASDAQ:ACXP) Q3 2023 Earnings Call Transcript

Acurx Pharmaceuticals, Inc. (NASDAQ:ACXP) Q3 2023 Earnings Call Transcript November 14, 2023 Acurx Pharmaceuticals, Inc. beats earnings expectations. Reported EPS is $-0.23952, expectations were $-0.28. Operator: Ladies and gentlemen, good morning, and welcome to the Acurx Pharmaceuticals Third Quarter 2023 Earnings Conference Call. At this time, all participants are in a listen-only mode. A brief […] ....

Canada , Philadelphia , Pennsylvania , United-states , Boston , Massachusetts , Kevin-garey , Dave-luci , Robert-deluccia , Bob-deluccia , Robert-shawah , Rob-shawah